As pharma companies look for ways to improve chronic disease management, AstraZeneca and Eli Lilly are exploring opportunities in remote patient monitoring.
Rising rates of chronic disease coupled with surging healthcare costs are creating a barrier to healthcare for the chronically ill. In response, pharma companies are exploring ways to improve at-home management solutions for chronic conditions.
Remote patient monitoring (RPM) captures and analyzes patient data in real time to enable virtual care and ongoing disease management. The technology has emerged as a viable tool to improve the treatment and management of chronic conditions. Current solutions include wearables and self-diagnostic kits that track and monitor a patient’s vitals.